Folic acid-conjugated BSA nanocapsule (n-BSA–FA) for cancer targeted radiotherapy and imaging

sheng liang,xin jin,yufei ma,jun guo,hui wang
DOI: https://doi.org/10.1039/c5ra12804h
IF: 4.036
2015-01-01
RSC Advances
Abstract:New carrier systems have generated new opportunities to deliver drugs to specific targets. Capitalizing on recent achievements in the area of nanotechnology and nuclear medicine, we sought to develop a radiolabeled nano-drug that could accumulate in tumors via tumor-selective targeted delivery system and could treat the tumors with radionuclide. (125)/I-131-labeled nano-drug, [(125)/I-131]I-n-BSA-FA, was prepared in this paper, with high radiochemical yield and long stability in vitro. Pharmacokinetics and biodistribution studies, as well as SPECT/CT imaging of the radiolabeled nanoparticles, [I-125]I-n-BSA-FA, were performed on a mouse model of breast cancer. Accumulation of this drug in tumor peaked at 24 h after injection and was measured to be 11.3 percentage injected dose per gram (ID% per g). In addition, a therapeutic study was performed to evaluate the therapeutic effect of [I-131]I-n-BSA-FA. It completely retarded the tumor growth with only one injection. The nano-carrier drugs described here targeted malignant tumors and may be useful for both tumor imaging and tumor treatment combined in clinic.
What problem does this paper attempt to address?